FDA Streamlines Approval Pathway for Neurizon's ALS Drug NUZ-001

The U.S. Food and Drug Administration (FDA) has informed Neurizon Therapeutics that a single positive pivotal study could be sufficient for the approval of its lead drug, NUZ-001, for Amyotrophic Lateral Sclerosis (ALS). Neurizon has completed enrollment for its Phase 2/3 HEALEY ALS Platform Trial ahead of schedule, with topline results expected in mid-2027.